Clinical trial NCT03968224 - References

Diabetes Mellitus, Type 2 — Effectiveness of Dapagliflozin for Weight Loss

Citation(s)

•   American Diabetes Association
  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. doi: 10.2337/dc19-S002. Review.
•   American Diabetes Association
  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102. doi: 10.2337/dc19-S009. Review.
•   Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD; Endocrine Society
  Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015 Feb;100(2):342-62. doi: 10.1210/jc.2014-3415. Epub 2015 Jan 15. Erratum in: J Clin Endocrinol Metab. 2015 May;100(5):2135-6.
•   Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB
  Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014 Apr;8(4):262-75.e9. doi: 10.1016/j.jash.2014.01.007. Epub 2014 Jan 26. Review.
•   Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza A, Rivera-Dommarco JA
  [Prevalence of obesity in Mexican adults 2000-2012]. Salud Publica Mex. 2013;55 Suppl 2:S151-60. Spanish.
•   Barrera-Cruz A, Avila-Jiménez L, Cano-Pérez E, Molina-Ayala MA, Parrilla-Ortiz JI, Ramos-Hernández RI, Sosa-Caballero A, Sosa-Ruiz Mdel R, Gutiérrez-Aguilar J
  [Practice clinical guideline. Prevention, diagnosis and treatment of overweight and obesity]. Rev Med Inst Mex Seguro Soc. 2013 May-Jun;51(3):344-57. Review. Spanish.
•   Barrera-Cruz A, Rodríguez-González A, Molina-Ayala MA
  [The current state of obesity in Mexico]. Rev Med Inst Mex Seguro Soc. 2013 May-Jun;51(3):292-9. Spanish.
•   Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön MR, Paschke R
  Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes. 2005 Oct;113(9):534-7.
•   Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S
  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.
•   Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F
  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015 May;21(5):512-7. doi: 10.1038/nm.3828. Epub 2015 Apr 20.
•   Briasoulis A, Al Dhaybi O, Bakris GL
  SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 Jan 19;20(1):1. doi: 10.1007/s11886-018-0943-5. Review.
•   Calapkulu M, Cander S, Gul OO, Ersoy C
  Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center. Diabetes Metab Syndr. 2019 Jan - Feb;13(1):284-288. doi: 10.1016/j.dsx.2018.09.005. Epub 2018 Sep 8.
•   Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators
  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care. 2018 Dec;41(12):2552-2559. doi: 10.2337/dc18-1087. Epub 2018 Oct 23.
•   DeFronzo RA, Goodman AM
  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541-9.
•   Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA
  Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012 Aug;20(8):1645-52. doi: 10.1038/oby.2012.59. Epub 2012 Mar 8.
•   Erondu N, Desai M, Ways K, Meininger G
  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care. 2015 Sep;38(9):1680-6. doi: 10.2337/dc15-1251. Epub 2015 Jul 22.
•   Færch K, Amadid H, Nielsen LB, Ried-Larsen M, Karstoft K, Persson F, Jørgensen ME
  Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). BMJ Open. 2017 Jun 6;7(5):e013802. doi: 10.1136/bmjopen-2016-013802.
•   Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W
  Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001 Mar;86(3):1154-9.
•   Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, Durante-Montiel I, Sánchez-Rivera G, Valadez-Vega C, Morales-González JA
  Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011;12(5):3117-32. doi: 10.3390/ijms12053117. Epub 2011 May 13. Review.
•   Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ
  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27. Erratum in: J Clin Invest. 2014 Apr 1;124(4):1868.
•   Fioretto P, Giaccari A, Sesti G
  Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x. Review.
•   Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD
  Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18.
•   Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE
  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535. Erratum in: Endocr Pract. 2019 Feb;25(2):204.
•   García de la Torre N, Rubio MA, Bordiú E, Cabrerizo L, Aparicio E, Hernández C, Sánchez-Pernaute A, Díez-Valladares L, Torres AJ, Puente M, Charro AL
  Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008 Nov;93(11):4276-81. doi: 10.1210/jc.2007-1370. Epub 2008 Aug 19.
•   Goktas Z, Moustaid-Moussa N, Shen CL, Boylan M, Mo H, Wang S
  Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013 Jun 10;4:69. doi: 10.3389/fendo.2013.00069. eCollection 2013.
•   Goodarzi MO, Bryer-Ash M
  Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005 Nov;7(6):654-65. Review.
•   Gregor MF, Hotamisligil GS
  Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-45. doi: 10.1146/annurev-immunol-031210-101322. Review.
•   Hajer GR, van Haeften TW, Visseren FL
  Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008 Dec;29(24):2959-71. doi: 10.1093/eurheartj/ehn387. Epub 2008 Sep 5. Review.
•   Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR
  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.
•   Hattersley AT, Thorens B
  Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion. N Engl J Med. 2015 Sep 3;373(10):974-6. doi: 10.1056/NEJMcibr1506573.
•   Hermann LS, Karlsson JE, Sjöstrand A
  Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol. 1991;41(3):263-5.
•   Hotamisligil GS, Shargill NS, Spiegelman BM
  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91.
•   Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI
  Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 Dec;49(12):2063-9.
•   Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJ
  Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010 Jun;50(6):636-46. doi: 10.1177/0091270009352185. Epub 2010 Mar 3.
•   Idris I, Donnelly R
  Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009 Feb;11(2):79-88. doi: 10.1111/j.1463-1326.2008.00982.x. Review.
•   Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group
  Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740-50. doi: 10.2337/dc13-0467. Epub 2013 Oct 21.
•   Jayawardene D, Ward GM, O'Neal DN, Theverkalam G, MacIsaac AI, MacIsaac RJ
  New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering? Heart Lung Circ. 2014 Nov;23(11):997-1008. doi: 10.1016/j.hlc.2014.05.007. Epub 2014 Jun 10. Review.
•   Kalupahana NS, Moustaid-Moussa N, Claycombe KJ
  Immunity as a link between obesity and insulin resistance. Mol Aspects Med. 2012 Feb;33(1):26-34. doi: 10.1016/j.mam.2011.10.011. Epub 2011 Oct 21. Review.
•   Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A
  Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995 Oct 6;270(40):23780-4.
•   Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I
  Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019 Jan;131(1):31-42. doi: 10.1080/00325481.2019.1549459. Epub 2018 Nov 30. Review.
•   Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M
  Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558.
•   Leick L, Lindegaard B, Stensvold D, Plomgaard P, Saltin B, Pilegaard H
  Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise. Obesity (Silver Spring). 2007 Feb;15(2):356-63.
•   Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A
  Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015 Apr;6(2):61-7. doi: 10.1177/2042018814560735. Review.
•   List JF, Woo V, Morales E, Tang W, Fiedorek FT
  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009 Apr;32(4):650-7. doi: 10.2337/dc08-1863. Epub 2008 Dec 29.
•   Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo RA
  Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes. 1988 Nov;37(11):1470-7.
•   Mason EE, Doherty C, Maher JW, Scott DH, Rodriguez EM, Blommers TJ
  Super obesity and gastric reduction procedures. Gastroenterol Clin North Am. 1987 Sep;16(3):495-502.
•   Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN
  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008 Mar 13;51(5):1145-9. doi: 10.1021/jm701272q. Epub 2008 Feb 9.
•   Mogul HR, Peterson SJ, Weinstein BI, Zhang S, Southren AL
  Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia. Heart Dis. 2001 Sep-Oct;3(5):285-92.
•   Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E
  Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017 Aug;130:53-60. doi: 10.1016/j.diabres.2017.04.017. Epub 2017 May 18.
•   Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A
  Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. Review.
•   Nauck MA, Del Prato S, Durán-García S, Rohwedder K, Langkilde AM, Sugg J, Parikh SJ
  Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014 Nov;16(11):1111-20. doi: 10.1111/dom.12327. Epub 2014 Jul 10.
•   Nguyen NT, Ho HS, Palmer LS, Wolfe BM
  Laparoscopic Roux-en-Y gastric bypass for super/super obesity. Obes Surg. 1999 Aug;9(4):403-6.
•   Nogués Solán X, Sorli Redó ML, Villar García J
  [Tools to measure treatment adherence]. An Med Interna. 2007 Mar;24(3):138-41. Spanish.
•   Nowak A, Czkwianianc E
  A contemporary approach to body mass regulation mechanisms. Prz Gastroenterol. 2016;11(2):73-7. doi: 10.5114/pg.2016.60043. Epub 2016 May 19. Review.
•   Obesity: preventing and managing the global epidemic
  Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
•   Okamoto A, Yokokawa H, Sanada H, Naito T
  Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients. Drugs R D. 2016 Sep;16(3):255-261.
•   Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H
  T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
•   Orme M, Fenici P, Lomon ID, Wygant G, Townsend R, Roudaut M
  A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab Syndr. 2014 Jun 11;6:73. doi: 10.1186/1758-5996-6-73. eCollection 2014. Review.
•   Panee J
  Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012 Oct;60(1):1-12. doi: 10.1016/j.cyto.2012.06.018. Epub 2012 Jul 4. Review.
•   Patel PS, Buras ED, Balasubramanyam A
  The role of the immune system in obesity and insulin resistance. J Obes. 2013;2013:616193. doi: 10.1155/2013/616193. Epub 2013 Mar 21. Review.
•   Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB
  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1687-93. doi: 10.2337/dc15-0843. Epub 2015 Jun 15.
•   Pryor R, Cabreiro F
  Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015 Nov 1;471(3):307-22. doi: 10.1042/BJ20150497. Review.
•   Queipo-Ortuño MI, Escoté X, Ceperuelo-Mallafré V, Garrido-Sanchez L, Miranda M, Clemente-Postigo M, Pérez-Pérez R, Peral B, Cardona F, Fernández-Real JM, Tinahones FJ, Vendrell J
  FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS One. 2012;7(11):e48605. doi: 10.1371/journal.pone.0048605. Epub 2012 Nov 5.
•   Rizzello M, De Angelis F, Campanile FC, Silecchia G
  Effect of gastrointestinal surgical manipulation on metabolic syndrome: a focus on metabolic surgery. Gastroenterol Res Pract. 2012;2012:670418. doi: 10.1155/2012/670418. Epub 2012 Oct 22.
•   Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, Gómez-Humarán IM, Gaona-Pineda EB, Gómez-Acosta LM, Rivera-Dommarco JÁ, Hernández-Ávila M
  [Methodological design of the National Health and Nutrition Survey 2016]. Salud Publica Mex. 2017 May-Jun;59(3):299-305. doi: 10.21149/8593. Spanish.
•   Rosenstock J, Ferrannini E
  Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015 Sep;38(9):1638-42. doi: 10.2337/dc15-1380.
•   Rosenstock J, Vico M, Wei L, Salsali A, List JF
  Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.
•   Santo MA, Riccioppo D, Pajecki D, Cleva Rd, Kawamoto F, Cecconello I
  Preoperative weight loss in super-obese patients: study of the rate of weight loss and its effects on surgical morbidity. Clinics (Sao Paulo). 2014;69(12):828-34. doi: 10.6061/clinics/2014(12)07.
•   Saponaro C, Pattou F, Bonner C
  SGLT2 inhibition and glucagon secretion in humans. Diabetes Metab. 2018 Nov;44(5):383-385. doi: 10.1016/j.diabet.2018.06.005. Epub 2018 Jun 30. Review.
•   Scheen AJ
  An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019 Apr;18(4):295-311. doi: 10.1080/14740338.2019.1602116. Epub 2019 Apr 16. Review.
•   Schork A, Saynisch J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, Häring HU, Stefan N, Fritsche A, Artunc F
  Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019 Apr 5;18(1):46. doi: 10.1186/s12933-019-0852-y.
•   Senn JJ, Klover PJ, Nowak IA, Mooney RA
  Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002 Dec;51(12):3391-9.
•   Shepherd PR, Kahn BB
  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999 Jul 22;341(4):248-57. Review.
•   Steinberg GR
  Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle. 2007 Apr 15;6(8):888-94. Epub 2007 Apr 11. Review.
•   Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA
  The hormone resistin links obesity to diabetes. Nature. 2001 Jan 18;409(6818):307-12.
•   Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE
  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550-4.
•   Tilg H, Moschen AR
  Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond). 2008 Feb;114(4):275-88. doi: 10.1042/CS20070196. Review.
•   Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, Fujita T, Saito A, Arakawa K
  Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci. 2005 Apr 22;76(23):2655-68.
•   Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A
  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007. Review.
•   Vidal-Puig A, O'Rahilly S
  Resistin: a new link between obesity and insulin resistance? Clin Endocrinol (Oxf). 2001 Oct;55(4):437-8. Review.
•   Wang Z, Nakayama T
  Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;2010:535918. doi: 10.1155/2010/535918. Epub 2010 Aug 5.
•   Warne JP
  Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol. 2003 Jun;177(3):351-5. Review.
•   Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr
  Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 Dec;112(12):1796-808.
•   Wilding J, Bailey C, Rigney U, Blak B, Beekman W, Emmas C
  Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. Diabetes Ther. 2016 Dec;7(4):695-711. Epub 2016 Sep 1.
•   Wolf G
  Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev. 2007 May;65(5):251-6. Review.
•   Wood IS, Trayhurn P
  Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003 Jan;89(1):3-9. Review.
•   Yanovski SZ, Yanovski JA
  Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361. Review.
•   Zhang Q, Dou J, Lu J
  Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract. 2014 Sep;105(3):313-21. doi: 10.1016/j.diabres.2014.06.006. Epub 2014 Jun 22. Review.

Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III

Details for clinical trial NCT03968224